Try our beta test site

CAPPA-2: Cisplatin Added to Gemcitabine in Poor Performance Advanced NSCLC Patients (CAPPA-2)

This study has been terminated.
(scarce enrolment and presentation of positive results of similar study in June 2012.)
Sponsor:
Collaborators:
Clinical Trials Promoting Group (APRIC/CTPG)
Gruppo Oncologico del Lazio (GOL)
Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
Gruppo Oncologico Italiano di Ricerca Clinica(GOIRC)
Gruppo Oncologico Italia Meridionale
Northwest Oncology Cooperative Group(GONO)
Information provided by (Responsible Party):
National Cancer Institute, Naples
ClinicalTrials.gov Identifier:
NCT00526643
First received: September 6, 2007
Last updated: March 27, 2017
Last verified: March 2017